Evidence map›Paper›PMID 38038260›Full record

ArticleNucleic acids research2024

Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II.

Afif F Bandak, Tim R Blower, Karin C Nitiss, Viraj Shah, John L Nitiss, James M Berger

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Topoisomerase II N-terminal ATPase Clamp Stabilization.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Article
  4. Genome Instability Induced by Topoisomerase Misfunction.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Afif F BandakJohns Hopkins University School of Medicine, Department of Biophysics and Biophysical Chemistry, Baltimore, MD 21205, USA.
Tim R BlowerJohns Hopkins University School of Medicine, Department of Biophysics and Biophysical Chemistry, Baltimore, MD 21205, USA.ORCID 0000-0002-7390-6458
Karin C NitissPharmaceutical Sciences Department, University of Illinois College of Pharmacy, 1601 Parkview Avenue, Rockford, IL 61107, USA.ORCID 0000-0002-3548-5090
Viraj ShahPharmaceutical Sciences Department, University of Illinois College of Pharmacy, 1601 Parkview Avenue, Rockford, IL 61107, USA.
John L NitissPharmaceutical Sciences Department, University of Illinois College of Pharmacy, 1601 Parkview Avenue, Rockford, IL 61107, USA.ORCID 0000-0002-1013-4972
James M BergerJohns Hopkins University School of Medicine, Department of Biophysics and Biophysical Chemistry, Baltimore, MD 21205, USA.ORCID 0000-0003-0666-1240
Johns Hopkins University · USUniversity of Illinois Urbana-Champaign · US

Funding

PROGRAM IN MOLECULAR BIOPHYSICST32GM008403 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BARRICK, DOUGLAS E. · 1990 to 2019
$13.5M
Structural and Biochemical Analyses of Type II DNA TopoisomerasesR01CA077373 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI BERGER, JAMES M. · 1999 to 2021
$7.6M
Understanding and exploiting DNA topoisomerases in cancer biologyR35CA263778 · NCI · JOHNS HOPKINS UNIVERSITY · PI James M. Berger · 2021 to 2026
$5.0M
Novel approaches for studying topoisomerase 2 targeting anti-cancer drugsR03CA216010 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI NITISS, JOHN L · 2017 to 2018
$160k
Genome Instability induced in cancer cells carrying mutations in Type II topoisomerasesR03CA259884 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI NITISS, JOHN L · 2022 to 2023
$160k
DNA Topoisomerase Misfunctioning in Neurological DiseaseR03NS116666 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI NITISS, KARIN · 2021 to 2022
$160k
NCI NIH HHS R01 CA077373NCI NIH HHS R03 CA216010NCI NIH HHS R03 CA259884NCI NIH HHS R35 CA263778NIGMS NIH HHS T32 GM008403NIH HHS T32-GM008403-28NINDS NIH HHS R03 NS116666
6 · The paper itself

Abstract

Type II topoisomerases effect topological changes in DNA by cutting a single duplex, passing a second duplex through the break, and resealing the broken strand in an ATP-coupled reaction cycle. Curiously, most type II topoisomerases (topos II, IV and VI) catalyze DNA transformations that are energetically favorable, such as the removal of superhelical strain; why ATP is required for such reactions is unknown. Here, using human topoisomerase IIβ (hTOP2β) as a model, we show that the ATPase domains of the enzyme are not required for DNA strand passage, but that their loss elevates the enzyme's propensity for DNA damage. The unstructured C-terminal domains (CTDs) of hTOP2β strongly potentiate strand passage activity in ATPase-less enzymes, as do cleavage-prone mutations that confer hypersensitivity to the chemotherapeutic agent etoposide. The presence of either the CTD or the mutations lead ATPase-less enzymes to promote even greater levels of DNA cleavage in vitro, as well as in vivo. By contrast, aberrant cleavage phenotypes of these topo II variants is significantly repressed when the ATPase domains are present. Our findings are consistent with the proposal that type II topoisomerases acquired ATPase function to maintain high levels of catalytic activity while minimizing inappropriate DNA damage.

Indexed as

DNADNA Topoisomerases, Type IIAdenosine TriphosphatasesAdenosine TriphosphateDNA DamageEtoposideHumansAdenosine TriphosphatasesAdenosine TriphosphateDNADNA Topoisomerases, Type IIEtoposide

Identifiers

PMID38038260
PMCPMC10853770
OpenAlexW4389242411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.